Huntington's disease (HD) is a fatal neurodegenerative disease with motor, cognitive and psychiatric impairment. Dysfunctions in HD models have been related to reduced levels of striatal brain-derived neurotrophic factor (BDNF) and imbalance between its receptors TrkB and p75(NTR). Thus, molecules with activity on the BDNF/TrkB/p75 system can have therapeutic potential. 7,8-Dihydroxyflavone (7,8-DHF) was described as a TrkB agonist in several models of neuro-degenerative diseases, however, its TrkB activation profile needs further investigation due to its pleiotropic properties and divergence from BDNF effect. To investigate this, we used in vitro and in vivo models of HD to dissect TrkB activation upon 7,8-DHF treatment. 7,8-DHF treatment in primary cultures showed phosphorylation of TrkB Y816 but not TrkB Y515 with activation of the PLCc1 pathway leading to morphological and functional improvements. Chronic administration of 7,8-DHF delayed motor deficits in R6/1 mice and reversed deficits on the Novel Object Recognition Test (NORT) at 17 weeks. Morphological and biochemical analyses revealed improved striatal levels of enkephalin, and prevention of striatal volume loss. We found a TrkB Y816 but not TrkB Y515 phosphorylation recovery in striatum concordant with in vitro results. Additionally, 7,8-DHF normalized striatal levels of induced and neuronal nitric oxide synthase (iNOS and nNOS, respectively) and ameliorated the imbalance of p75/TrkB. Our results provide new insights into the mechanism of action of 7,8-DHF suggesting that its effect through the TrkB receptor in striatum is via selective phosphorylation of its Y816 residue and activation of PLCc1 pathway, but pleiotropic effects of the drug also contribute to its therapeutic potential. † Present address:
Introduction
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expansion of CAG repeats on the huntingtin gene (htt) (1) . The clinical course of the disease includes motor abnormalities that progresses towards serious disability and death. Additionally, cognitive and behavioural impairments show increased prominence in HD patients as they precede motor symptoms by at least 15 years (2) . A pathological hallmark of HD is the preferential degeneration of medium sized spiny neurons in the striatum (3, 4) , with the earliest loss corresponding to the neuronal populations expressing GABA/enkephalin that project to the lateral globus pallidus (5) . Several hypotheses have been proposed to explain this preferential degeneration. It has been suggested that the lack of neurotrophic support plays a major role, since the reduced neurotrophin levels renders striatal neurons more vulnerable to the toxic action of mutant htt (6) (7) (8) (9) .
Brain-derived neutrotrophic factor (BDNF) is the most potent neurotrophic factor promoting development, neurite outgrowth, synaptic plasticity and the survival of medium-sized spiny neurons (10) (11) (12) (13) (14) (15) . BDNF deficits are a major contributor to HD pathogenesis. In support of this view, BDNF levels are abnormally low in brain tissue from both human HD patients, (7, 16) and murine HD models (17, 18) . It has been determined that mutant htt decreases striatal BDNF by interfering with BDNF synthesis and transport (6, 19, 20) . Changes in striatal gene expression profile are similar in mice with BDNF deficiency and HD patients (21) . Finally, it has also been observed that the restoration of striatal BDNF levels can delay the onset and ameliorate the cognitive and motor deficits in mouse models of HD (22, 23) . Thus, BDNF activation of its most specific receptor TrkB is a candidate for neuroprotective therapeutic strategies in HD (24) .
The activation of the BDNF receptor TrkB leads to autophosphorylation of its tyrosine residues, triggering multiple intracellular signalling cascades (25) . Three major pathways are activated by TrkB depending on the specific phosphorylated residue. On the one hand, for TrkB Y515 two main cascades are initiated, the PI-3-kinase pathway that activates AKT and mediates anti-apoptotic effects, and the MAP/ERK pathway that activates regulators of protein translation. On the other hand, TrkB Y816 phosphorylation engages the PLC-c1 pathway leading to the production of diacylglycerol, increasing intracellular calcium with subsequent activation of PKC and CAM Kinases (26, 27) . The regulation of these diverse signalling cascades incorporates BDNF in a variety of additional neuronal functions, such as synaptic reorganization processes which includes the formation and maintenance of dendrites and dendritic spines (28, 29) , which in turn influences synaptic plasticity including effects on cognitive function (30) . Additionally, BDNF and particularly its precursor pro-BDNF can bind the p75 receptor which is regarded as a negative modulator of synaptic plasticity (31) , since recent studies indicate that inhibiting p75 might be beneficial for neuron maintenance in pathological states (32) . Therefore, the imbalance between the BDNF-TrkB-p75 signalling has to be considered for developing new neuroprotective treatments in HD (33, 34) . One approach to overcome the limitations of a proteinbased therapeutic has been to develop small-molecule TrkB agonists. Recently, a compound termed 7,8-Dihydroxyflavone (7, was identified as a putative TrkB agonist with BDNFlike effects in vivo and in vitro (35) . 7,8-DHF has been used in various neurodegenerative disease models with promising therapeutic potential, including Rett syndrome (36), Alzheimer's (37) , and Parkinson's Disease (38, 39) . A previous work in HD has shown histological and motor improvement (40) . However, various studies have found seemingly contradictory results for 7,8-DHF as a TrkB agonist, and identified alternative TrkB independent therapeutic processes (41) (42) (43) . In this work, we identified the signalling pathways triggered by 7,8-DHF-dependent TrkB activation, and compared them to BDNF effect, showing the potential neuroprotective effects of 7,8-DHF to recover cognitive and motor deficits in the mouse R6/1 HD model. We found that 7,8-DHF delayed the starting of functional deficits, lowered htt aggregate count, and consistently and robustly activated the PLCc1 pathway through selective phosphorylation of TrkB Y816 . of striatal primary cultures (B,C) corroborate-specific phosphorylation of Y816 residue as well as PLCc1 pathway activation. Cells were cultured for 14 DIV under basal conditions, and then treated for 30 min with described doses of 7,8-DHF or BDNF 100 ng/ml. n ¼ 4-6 independent cultures per condition. Statistical analysis was performed using one-way ANOVA (**P < 0.01, *P < 0.05 post-hoc Fisher LSD vs CTR).
Results
10 ng/ml BDNF. Additionally, to ensure that the morphological effect was specific through PLCc1, we used the inhibitor U-73122 (0.5 lM). Three days later, we counted the number of calbindin positive neurons to make sure there were no differences among cultures (Supplementary Material, Fig. S1B ) and then analysed the neuritic complexity through an automated image analysis pipeline ( Fig. 2A, Supplementary Material, Fig. S2 ). We did not observe any differences on the number of neurites (endpoints) between WT and R6/1 cultures in basal conditions (Fig. 2B) (47, 48) . We therefore evaluated neuronal activity differences at the network level in WT and R6/1 primary striatal neurons. We proceeded by recording spontaneous activity in small, 4 mm diameter cultures containing striatal neurons at DIV 10, as shown in Figure 3A . We monitored the activity through calcium imaging via the probe Fluo-4, which allows the detection of calcium transients upon neuronal firing with good spatial and temporal resolution. To quantify differences on activity patterns, we selected the area occupied by each culture on each experiment recording, and divided it into 500-700 12px squaredshaped Regions of Interest (ROIs). Each ROI contained 8 to 10 cells and was recorded for 15 min. After obtaining the fluorescence changes for each ROI and plotting them into traces, we could automatically select the active portion of each culture (ROIs that fluctuated their fluorescence signal more than 1.3 SD deviations from a known ROI containing no cells). We aggregated data from 6 to 8 cultures and found that WT cultures displayed a significantly higher proportion of active ROIs compared to HD cultures (two-way ANOVA, genotype effect, F(1,39) ¼ 78.51 P < 0.001). Remarkably 7,8-DHF induced a significantly larger proportion of active ROIs compared to BDNF on HD cultures (P < 0.05, Fisher's LSD post-hoc) (Fig. 3B) though not enough to overcome HD-reduction in the number of active neurons.
To further investigate the type of changes elicited by BDNF and 7,8-DHF, we also obtained detailed information on the specific type of activity each treatment induces. The average trace from a culture of each condition depicting changes during 200s (t 0 ¼ 200, t 1 ¼ 400) is included in Figures 3C-E to better illustrate the typical activity. We first observed considerable differences between WT and R6/1 cultures in control conditions (Fig. 3C) , with WT cultures presenting clear, highly periodic peaks of strongly synchronized activity, while R6/1 cultures, by contrast, displaying a noisy signal with low amplitude peaks that indicated poor activity and communication. Furthermore, BDNF administration on WT cultures resulted in a remarkable boost in both activity and synchronization (Fig. 3D left) , while R6/1 cultures did not modify their firing patterns upon BDNF treatment (Fig. 3D right) (40), we tested whether 7,8-DHF administration in vivo could have beneficial effects on other HD models such as R6/1 mice. Our experiments consisted in administering 7,8-DHF (orally at 5mg/kg/day) starting at presymptomatic stages (8 weeks) and continuing up to 20 weeks of age. 7,8-DHF treatment was unable to revert or delay the expected weight loss of R6/1 (Fig. 4A ). To analyse whether 7,8-DHF delayed motor deficits, animals were subjected to the rotarod test. R6/1 mice showed deficits in motor performance at all the speeds tested. 7,8-DHF treatment did not modify the motor performance of WT, but was able to partially ameliorate the motor deficits found in R6/1 mice. Weekly performance curves show detail on motor function upon 7,8-DHF administration (Fig. 4B ). Week to week differences between R6/1 groups were more evident at higher speeds (24 and 32 rpm.), and reached statistical significance at week 16 (Fisher's LSD post-hoc). In general, the performance curve of the Rotarod strongly suggests a delay on the onset of motor deficits although, intriguingly, only distinguishable at high speeds of the test. Finally, we evaluated whether 7,8-DHF improved long-term memory deficits in HD by performing the novel object recognition test (NORT) at 17 weeks of age. We found that, whereas WT mice spent significantly more time exploring the new object than the old one, this preference was lost in R6/1 mice implying impaired cognitive function, as previously described. Notably, chronically treated R6/1 mice showed a similar preference for the new object as WT mice (Fig. 4D ), strongly indicating that the deficit was reversed.
Chronic 7,8-DHF treatment prevents striatal volume decline, decreases mutant Huntingtin aggregates and reverses enkephalin striatal protein level deficits in R6/1 mice Striatal volume loss is a pathological hallmark extensively described in HD pathology which occurs in humans as a result of extensive loss of medium spiny neurons (49, 50) ; the R6/1 model of HD is absent of medium spiny neuron cell death, but striatal volume loss is also present, explained by smaller soma size of medium spiny neurons (51) . Accordingly, we observed a significant decrease in striatal volume in R6/1 mice compared to WT, that was only significant for the R6/1 vehicle group, suggesting that 7,8-DHF delays striatal volume loss at this age (Fig. 5A) . Next, we counted DARPP32 positive neurons finding no significant changes in any group as expected (Fig. 5B) . In contrast, when we measured the cross transversal area of DARPP32 positive cells, there was a significant difference between the R6/1 control and 7,8-DHF treated group, although soma size was still significantly decreased compared to WT groups (Fig. 5C ). This indicates a partial recovery of the neuron atrophy described for HD models. These histological results suggest that 7,8-DHF minimizes striatal volume loss through prevention of atrophy in medium spiny neurons.
In addition, lower levels DARPP32 correlate with HD pathology (52). We found significantly reduced levels of DARPP-32 in the striatum of R6/1 mice, which 7,8-DHF treatment was not able to prevent (Fig. 5D ). To explore this difference further, we quantified protein levels of markers for the main subpopulations of DARP32 positive cells, such as enkephalin and substance P, which are related to striatopallidal and striatonigral pathways respectively. Enkephalin levels were significantly decreased in R6/1 control animals, whereas 7,8-DHF treated R6/1 mice had significantly higher levels of enkephalin comparable Endpoint (branches) (B) and total tree length quantification of neuronal cultures (C) For morphological assessments cells were treated at 7 DIV 1 mM 7,8-DHF or BDNF 10 ng/ml in the presence or absence of PLC inhibitor U-73122 (0.5 mM) and stained and analysed at DIV 10. n ¼ 4-6 independent cultures per condition Â 10-14 images per culture, containing at least 1 entire neuron on the field of vision were analysed (total neurons analysed n ¼ 60-82 per condition). Statistical analysis was performed using one-way ANOVA (**P < 0.01, *P < 0.05 post-hoc Fisher LSD vs WT CTR; ## P < 0.01, #### P < 0.0001 post-hoc Fisher LSD vs HD CTR).
to WT groups (Fig. 5E ). On the contrary, substance P levels remained unchanged between any group (Fig. 5F ). We next studied whether 7,8-DHF treatment could prevent or reduce mutant huntingtin aggregation which forms prominent intranuclear inclusions in striatum and are a pathological feature present on HD patients and transgenic murine HD models. Intranuclear inclusions of mutant huntingtin were stereologically counted on the striatum of R6/1 mice at 20 weeks of age with a statistically significant reduction in the total number (Fig. 5G) and density (Fig. 5H ) of striatal intranuclear inclusions in treated animals (Fig. 5I) . Additionally, we found a significant reduction of aggregated huntingtin levels (45.6%, P < 0.05 student's t-test) by blotting protein lysates of these animals. (Fig. 6B ) levels in striatum, whereas TrkB total levels remained unchanged (Fig. 6C ). In agreement with these results, pPLCc1 levels were also significantly increased by 7,8-DHF treatment in R6/1 striatal samples compared to R6/1 controls (Fig. 6D ). Finally, we tested whether 7,8-DHF could reverse the striatal p75/TrkB imbalance as previous work has described that functional improvement can be accompanied by a prevention of the increase in receptor p75 protein levels (32) . We found that 7,8-DHF was able to normalize p75 levels at 20 weeks of age in R6/1 mice (Fig. 6E ).
7,8-DHF treatment normalizes nNOS and iNOS expression in striatum, prevents cell death by oxidative stress and reverses p75 increased levels on in vitro models of HD Since BDNF-independent effects have been described for 7,8-DHF, we were interested in additional metabolic pathways that could be playing a role on the striatal effects that we measured. Previous studies have shown potent anti-inflammatory effects of 7,8-DHF (41, 53) . Thus, we aimed at investigating whether 7,8-DHF modified possible convergent pathways for BDNF action and inflammatory pathways such as nitric oxide (NO) metabolism (54) . To this end, we evaluated whether 7,8-DHF treatment modified levels of the main NO-producing enzymes in striatum, namely the inducible and neuronal NO synthases (iNOS and nNOS respectively). Our results show a prevention of decreased levels of nNOS in R6/1 mice by 7,8-DHF (Fig. 7A ) compatible with functional improvements (55) . By contrast, iNOS levels, which are more directly related with neuroinflammation (56), were increased in control R6/1 mice and this was reversed on 7,8-DHF treated animals (Fig. 7B) . To verify these results we performed an in vitro toxicity assay with a Hdh(Q7) striatal immortalized cell line adding H 2 O 2 (100 mM), BDNF (10 ng/ml), 7,8-DHF (1 mM) and the TrkB inhibitor K252a (100 nM). Cell death assessment with colourimetric CCK-8 revealed comparable capabilities of BDNF and 7,8-DHF to prevent cell death, but only 7,8-DHF maintained its protective effect upon addition of K252a (Fig. 7C) , suggesting a different mechanism from TrkB activation. Finally, we assessed 7,8-DHF capability to prevent p75 overexpression on HD striatal primary cultures upon addition of the inflammatory factor TNF-a (15 ng/ml) as we hypothesized its anti-inflammatory properties could be contributing to this recently described therapeutic mechanism (32) . Effectively, 7,8-DHF prevented the specific increase of p75 on HD cultures making the prevention of TrkB/p75 imbalance a likely contributor to functional effects of the treatment (Fig. 7D) .
Discussion
The present work provides evidence that 7,8-DHF treatment has potential as a therapeutic agent in HD, as we showed a strong prevention of motor symptoms, and provide the first evidence that 7,8-DHF has effects on cognitive deficits in HD.
Furthermore, our data suggest that, at least for striatal-related effects, 7,8-DHF action on the TrkB receptor is mediated through the selective activation of its Y816 residue and subsequent activation of downstream PLCc1 pathway. Additionally. 7,8-DHF displays pleiotropic engagement of metabolic pathways related to inflammation and the imbalance of p75/TrkB receptors that are likely contributors to therapeutic effects.
It is now widely reported that a general dysregulation of neurotrophic support exists in HD patients and HD animal models (7, 16, 23) . Great interest has been focused on BDNF, a significant contributor to HD pathology. Indeed, the specificity of (B); Soma size of DARPP32þ cells was significantly rescued with 7,8-DHF (C); There's a non-significant trend of maintenance of DARPP32 levels (D); cellular subpopulations markers of DARPP32þ cells in striatum, show a significant recovery of Enkephalin but not Substance P levels. (E,F) ; mhtt aggregates number and density are reduced with 7,8-DHF treatment (G,H), representative image of striatal aggregates (I). Statistical analysis was performed using two-way ANOVA (***P < 0.001, **P < 0.01, *P < 0.05, Post-hoc Fisher's LSD vs WT CTR or as depicted in graphs).
expression of its receptor TrkB on the ENKþ/Drd2 neurons of the striatopallidal pathway, which have been classically described as the earlier and most significantly damaged in HD patients and models, and the dependence of survival and function of the medium-sized spiny neurons on BDNF levels makes it a suitable target for therapeutic intervention (34, 57) . Nevertheless, adequate pharmacological interventions seeking to activate TrkB with mimetics or tailored antibodies, have proven challenging even after years of intensive research on neurotrophins and its receptors, as the whole extent of its biological effects is unknown. 7,8-DHF was originally described as a potent and selective TrkB agonist (thus a BDNF-mimetic), which elicited effects in vivo and in vitro (35) Consequently, numerous reports of biological effects congruent with a neuroprotective BDNF activity have been published in models of Parkinson (35) , Alzheimer (37) , and HD (40), as well as Rett Syndrome (36) and several models of anxiety, depression (58-60) and ischemic brain injury (61) . Notwithstanding these results, the precise molecular mechanism of 7,8-DHF induced TrkB activity has been proven variable and sometimes inconsistent between the different models examined. For example, neuroprotective and cell death preventive effects have been described for 7,8-DHF in models lacking TrkB expression (53, 62, 63) . Furthermore, the activation profile of TrkB has been checked inconsistently for its different residues in published studies (40, 43, 44) .
In light of these observations, specification of 7,8-DHF TrkB activation profile is needed in order to compare directly its effect in different models. For instance, a study by Todd et al. (43) was unable to detect any phosphorylation of TrkB in different cortico-striatal models. In contrast, a complete panel of 7,8-DHF induced phosphorylations of TrkB in cortical cultures published by Ye's group (44) found that 7,8-DHF was able to engage all main phosphorylation sites of the receptor in mature cultures. Their data support that TrkB activation profile varies depending upon state and maturation of the receptor protein and is likely different for small molecules than for BDNF. Comparing these unchanged (C); complementarily PLCc1 phosphorylation levels were increased in treated animals (D); 7,8-DHF treatment was also capable of preventing p75 increase on R6/1 mice (E) the mild increase in p75 in HD mice is not significant. 7,8-DHF however reduces partially p75 levels. Statistical analysis was performed using two-way ANOVA (***P < 0.001, *P < 0.05, post-hoc Fisher's LSD).
results, it should be noted that different phosphorylation sites are checked in those two works: Todd's models rely on pTrkB Y515 on a cortico-striatal neuronal model, while Ye's paper performs the whole battery of downstream TrkB phosphorylation profile in cortical cultures, and it is indeed evident that the strength of activation is also lower for TrkB Y515 upon 7,8-DHF administration than for TrkB Y816 in all models checked.
Our study neatly reconciles these diverging views on the effect of 7,8-DHF upon TrkB, as we described that it can reliably act as a specific agonist for TrkB Y816 phosphorylation in a striatal paradigm. Furthermore, this proposed model is consistent with several observations on the neuroprotective effect of 7,8-DHF. Firstly, our in vitro results showed similar but discernible effects between 7,8-DHF and BDNF on striatal neuronal cultures. Early administration of BDNF changes the ratio of calbindin-positive neurons and thus intervenes in neuronal fate decision with an increase of calbindin phenotype dependent on Akt/Erk pathway activation (10). Our long-term treatment of WT striatal cultures corroborated this effect for BDNF while 7,8-DHF treatment did not modify the number of calbindin-positive cells. Surprisingly, for HD cultures no treatment was sufficient to obtain a calbindin-positive neuron count increase, suggesting a possible difference in downstream pathway maturation of the TrkB receptor in HD (64), which is in agreement with a recently published study that showed attenuated response to BDNF in R6/2 striatal primary cultures (65) . Morphological beneficial effects of BDNF and 7,8-DHF were comparable on striatal cultures, with a marked improved arborisation in both HD and WT phenotypes. This might be explained by the effects of specific PLCc1 activation in developing neurons since it is widely reported that PLC-c1 activation induces neurite outgrowth. Indeed, PLC-c1 is a very well characterized downstream effector of several pathways related to neuronal arborisation and neurite outgrowth, including the aforementioned BDNF/TrkB pathway but also fibroblast growth factor (FGF) through its receptor (FGFR) (66) (67) (68) . The fact that 7,8-DHF treatment on striatal primary cultures was able to improve morphology on R6/1 cultures at the equal levels to post-BDNF treatment, might be related to a decrease of phosphorylation of PLCc1 which is consistently reported on HD models (69) . In contrast, other intracellular pathways downstream of TrkB (Erk1-2/Akt) are variable on their state of activation. Therefore, is possible that correcting PLC-c1 activity is sufficient for striatal neurons to thrive. Altogether, the morphological effects of selective activation of PLC-c1 downstream pathways via 7,8-DHF suggest that not only stronger activation of TrkB is needed to prevent deficits on HD, but that a balance between the TrkB downstream pathways could be necessary for establishing neuronal homeostasis. BDNF and its action through the TrkB receptor has been linked in many studies to the functional capabilities of neuronal cultures. Semi-chronic BDNF administration to neuronal networks has proven to change the inhibitory/excitatory neuron rate (70) , change firing properties (71) and vulnerability to excitotoxicity (72) . Less is known about the acute effects of BDNF infusion on neuronal networks. It is described that in the cortical neurons acute administration of BDNF induces glutamate release that modulates spontaneous calcium firings, through a PLCc1 dependent mechanism that also correlates with higher expression of this protein during neuronal development (73) . Mature striatal neuronal networks contain a higher ratio of GABAergic to glutamatergic activity than cortical networks, and PLCc1 modulation is directly involved in the modulation of Ca þþ spontaneous firing characteristics in both kinds of synapses and should synergically contribute to a higher excitation rate (74) . In brief, in a glutamatergic context PLCc1 activation increases neuronal excitability with prevention of excitotoxicity through specific modulation of NR2B-containing NMDAR, whereas in a GABAergic context, PLCc1 increases the release of GABA but reduces its receptor activation resulting in an inhibition of GABA-mediated fast-hyperpolarization (reviewed by Jang et al. 2013) (75) . Concordantly, treatment with 7,8-DHF in striatal cultures elicited a rhythmic and synchronized response that was remarkably similar in WT and R6/1 derived cultures. This is in accordance with the capability of 7,8-DHF to obtain morphology changes in HD cultures, and also might give some insight into the differential development of TrkB downstream pathways in R6/1 mice in the early neuronal development, as other groups have suggested that HD dysfunction has hallmarks of having a component of neurodevelopmental disorder (76) (77) (78) . Although some studies have described calcium dysregulation in HD derived cultures, most of them focus on the cellular, or subcellular (synaptic) level (79, 80) and have been performed on cortico-striatal cultures or brain slices. Our approach to simultaneous recording of calcium activity on whole neuronal cultures allowed to discern basal differences between the activity pattern with significantly fewer neurons displaying detectable calcium changes in HD cultures (Fig. 3B) . Remarkably, BDNF administration in HD cultures was unable to significantly alter either the fraction of active neurons in culture, nor their pattern of activity, which is in line with recent studies that show an impaired response to BDNF in striatal cultures derived from other HD models such as R6/2 mice (65). Moreover, even when treatment with BDNF and 7,8-DHF was administered in a short pulse of 15 min before recording, morphological differences (such as the total tree length deficit described in Fig. 2C ) might contribute to the impaired basal activity found in HD cultures. Nevertheless, based on our results, we can conclude that the increase in neuronal activity elicited by 7,8-DHF suggests that it is able to bypass basal deficits in contrast with BDNF since 7,8-DHF is able to recruit more neurons into producing detectable activity, albeit the direct implication of PLCc1 on calcium signalling provides a difficult interpretation of its properties.
Altogether, in vitro results from HD culture treatment with 7,8-DHF show that: 7,8-DHF has a differential effects from BDNF, demonstrated by the different TrkB phosphorylation profile and pattern of neuronal activity; and 7,8-DHF semi-chronic treatment improves morphology dependent on PLCc1 which could translate to functional improvements in vivo.
7,8-DHF has shown therapeutic potential on many central nervous system disease models, in particular, it has been shown to confer partial recovery of motor function in the HD murine model N171-82Q (40). Our motor results showed a robust effect on motor behaviour with 7,8-DHF treatment, congruent with specific activation of PLCc1. Complementarily, an increasing amount of evidence demonstrates that cognitive deficits precede the onset of motor symptoms HD patients, which is in accordance with mouse models of the disease where neuronal dysfunction but not death is sufficient to obtain a characteristic pathological phenotype. In this respect, we describe for the first time significant improvement in long-term memory deficits in an HD model by chronical treatment of 7,8-DHF. PLCc1 has been directly and specifically implicated in long-term memory tasks dependent on unimpaired hippocampal LTP since PLCc1 activation through TrkB is sufficient to maintain hippocampal LTP (47) , whereas Shc activation is not required (48) . Additionally, PLCc1 specific effects have been observed in other brain diseases, for instance, antidepressant drugs have been found to increase selectively TrkB/PLCc1 signal without Shc activation (81, 82) . Thus, all previously described PLCc1-specific mechanisms probably act synergistically to a general phenotype improvement in our mouse model with the possibility of being translated to therapeutic applications.
Finally, as a member of the flavonoid family, 7,8-DHF exhibits numerous potential pleiotropic characteristics. TrkBindependent oxidative stress reduction and anti-inflammatory properties have been described for this compound as demonstrated in 7,8-DHF assays showing protection from ischemia and against direct toxicity from diverse agents (53, 83, 84) . Concordantly, we found a normalisation of nNOS levels in striatum compatible with reported improvements in cognition (55) accompanied by a decrease of iNOS levels, an intermediary in oxidative stress and inflammatory responses, as well as strong hints that 7,8-DHF properties have the capability to restore TrkB/p75 imbalance with beneficial effects in HD. Indeed, it has been recently published that therapies with the capability of reverting this TrkB/p75 imbalance (32) hold the potential of addressing different pathophysiological mechanisms on HD, concurrent with the lack of neurotrophin support. Based only on our study, the relative contribution of 7,8-DHF TrkBindependent effects is difficult to determine, although the prevailing literature on the relationship between HD pathology and neurotrophic support shows that restoring or increasing striatal levels of BDNF is sufficient to delay functional impairment (85-88) whereas anti-inflammatory interventions result in milder improvements or no differences in HD models. For instance, treatment with either acetylsalicylate or rofecoxib was not neuroprotective in R6/2 mice (89); while another antiinflammatory and antioxidant compound, BN82451, significantly, but transiently improved symptoms on the same model (90) . Furthermore, even the striatal gene transfer of dominant negative tumour necrosis factor was not able to rescue medium sized spiny neurons in the YAC128 mouse model of HD (91) .
Finally, in the original work where 7,8-DHF was identified as a TrkB agonist (92) they use the F616A knock-in mice that exhibit a TrkB-null phenotype upon treatment with the substance 1NMPP1; they found that 7,8-DHF apoptosis prevention against kainic acid and ischaemia was lost when the animals were effectively deprived of TrkB signalling, concomitantly with 7,8-DHF administration. This gives strong hints that the effect of 7,8-DHF through TrkB is at least a main contributor to its beneficial effects. Regarding TrkB/p75 imbalance, recent studies have shown that it affects HD pathology prominently (33) , but therapeutic interventions focusing on restoring neurotrophic receptor balance are scarce, since the only paper describing p75 normalization via drug administration in HD used the compound FTY720 (Fingolimod) which has also been shown to increase BDNF levels that should involve TrkB activation (32) . Considering all this together, though 7,8-DHF therapeutic effects on the R6/1 model could be explained through its effect on the TrkB pathway, further studies are needed to discard the possibility that its TrkBindependent effects might be as relevant.
In summary, we provide compelling evidence that 7,8-DHF administration improves motor and cognitive function in R6/1 mice. We propose the activation of the TrkB Y816 phosphorylation and engagement of PLCc1 in the R6/1 striatum as a mechanism for biological effects of 7,8-DHF (Fig. 8) . Furthermore, 7,8-DHF's pleiotropic effects on inflammation and p75 upregulation provide additional pathways with therapeutic benefit in HD, and underscore the therapeutic potential of 7,8-DHF for functional motor and cognitive deficits. Lastly, our findings suggest that the interaction between 7,8-DHF and TrkB receptor is complex and sensitive to the model studied. Nevertheless, the ability of 7,8-DHF to elicit even partial agonism of TrkB merits further study since its neuroprotective effects are robust and well described.
Materials and Methods

Mice
Male R6/1 transgenic mice expressing exon-1 of mhtt were from Jackson Laboratory (Bar Harbor, ME, USA) and maintained in a B6CBA background. WT littermate animals were used as controls. Genotypes were determined by polymerase chain reaction (PCR). CAG repeat length was determined as previously described (HDCRG, 1993). Our R6/1 colony has 145 CAG repeats (72) . Experiments were conducted in a blind-coded manner respect to genotype and treatment condition of mice. 
Behavioural tests
Novel object recognition test (NORT). NORT was performed at 17 weeks of age as previously described (69) . Briefly, after 3 days of habituation to the open field, two similar objects were presented to each mouse and 24h later one of them was changed by a new object. Object preference was measured as the percentage of time exploring each object, using SMART junior software (Panlab).
Striatal neuronal cultures
Primary striatal neuronal cultures were performed as previously described (46) . Brains from 18-day old WT and R6/1 mouse embryos were excised and placed in sterile phosphate-buffered saline (PBS), pH 7.4. The striatum was then dissected and gently dissociated with a fire-polished Pasteur pipette. Cells were plated onto 6-well plates pre-coated with 0.1 mg/ml poly-Dlysine at a density of 50 000 cells/cm 2 . Neurobasal medium supplemented with B-27 and Glutamax (Gibco) was used to grow the cells in serum-free conditions. Cell cultures were maintained in an incubator with 5% CO 2 at 37 C. Neuronal cells represented more than 95% of the cell population. For biochemical and immunofluorescence assay of TrkB phosphorylation activity, cultures were treated at 14 days in vitro (DIV) with vehicle (DMSO 0.1%), 7,8-DHF (1 m with DMSO concentration adjusted to 0.1%) and BDNF (100 ng/ml; Peprotech EC Ltd., London, UK þ 0.1% of DMSO). For morphology analyses cultures were treated at 3 or 7 (DIV) with vehicle (DMSO 0.1%), 7,8-DHF (at described doses with DMSO concentration adjusted to 0.1%), BDNF (10 ng/ml; Peprotech EC Ltd., London, UK þ 0.1% of DMSO) and the PLCc1 inhibitor (U-73312 0.5 mM Sigma) and assessed either 7 or 3 days after. For p75 increase assay, media changes were performed weekly and cells were treated after 21 DIV. TNFa (Life Technologies) was added to the culture at a concentration of 10 ng/ml and 7,8-DHF was used at 1 mM (all cultures were adjusted to 0.1% DMSO to control for the DMSO diluted drugs). 8 h after treatment, cells were washed with cold PBS and lysed for WB analysis.
Immunocytochemical staining and branching analysis
Immunocytochemical staining was performed as previously described (93) . Briefly, fixed cells were permeabilized in 0.1% saponin for 10 min and then blocking was performed with 1% BSA in PBS for 1 h. Cells were incubated overnight with the primary antibody anti-MAP2 (1:500; Sigma-Aldrich). Afterwards, cells were incubated with fluorescent secondary antibody, Cyanine 3 antimouse (1:150; Jackson ImmunoReseach, West Grove, PA). After washing twice with PBS, the coverslips were mounted with mowiol. Striatal neuron staining was observed with a fluorescence microscope (Olympus). At least 30 neurons were randomly selected for each embryo and each condition. Automated quantification of branches, and neurite length was performed using Cell Profiler v2.8 software. All the analysis was performed in a blinded fashion.
Calcium imaging
For measuring spontaneous calcium activity we used Fluo-4-AM as fluorescence probe, and both fluorescence probe loading and activity recording protocols were identical as the ones previously described (94, 95) . Briefly, mouse primary striatal cultures were incubated for 15 min with either 500 nM 7,8-DHF or 100 ng/ml BDNF in pH-stable recording medium in the presence of 0.4% of the cell-permeant calcium sensitive dye Fluo-4-AM (Invitrogen). The culture was washed with fresh medium after incubation and finally placed in a recording chamber for observation. The recording chamber was mounted on a Zeiss inverted microscope equipped with a Hamamatsu Orca Flash 2.8 CMOS camera. Fluorescence images were acquired with a speed of 33 frames per second and a spatial resolution of 12.4 mm/pixel. To analyse the acquired data, we used a custom developed software in Matlab V R in which we divided each culture in 500-700 regions of interest (ROIs) that contained on the order of 6-8 individual neurons, and then extracted the average fluorescence level of each ROI as a function of time (94) (95) (96) .
Immunohistochemistry
For immunohistochemical analysis, brains were fixed by immersion in paraformaldehyde (Sigma) 4% in PBS, cryoprotected in PBS/Sucrose 30% and frozen in methyl-butane (Sigma). 30 mm thick coronal sections of the brain were obtained using a cryostat (Microm) and kept as free-floating sections.
Immunohistochemistry was performed as previously described (69) . Diaminobenzidine immunohistochemistry was performed as previously described (23) . Tissue was incubated with rabbit anti-DARPP32 (1:100, Promega), and anti-EM48 (1:100; Millipore). Sections were washed three times in PBS, incubated with biotinylated secondary antibody (1:200; Thermo Fisher, Rockford, IL), and developed as previously described (Giralt et al. 2011) . To determine the number of neuronal intra-nuclear inclusions (NIIs) in the different areas of the striatum, unbiased counting for treatment was performed with Computer-Assisted Stereology Toolbox (CAST) software (Olympus Danmark A/S). We used the dissector counting procedure in coronal sections spaced 240 lm apart, as described elsewhere (97) . Six animals per condition were used.
Western blot
After killing the animals by cervical dislocation the striatum was rapidly removed and homogenized. Protein extraction and western blotting were performed as described elsewhere (23) . Immunoblots were probed with the following antibodies ( . Immunoreactive bands were visualized using the Western Blotting Luminol Reagent (Santa Cruz Biotechnology) and quantified by a computerassisted densitometer (Gel-Pro Analyzer). Discontinued bands indicate that samples were run in the same gel but were not contiguous.
Cell cultures
The conditionally immortalized wild-type ST7/7Q striatal neuronal progenitor cell line expressing endogenous levels of normal huntingtin with 7 glutamines was used as previously described (98) . Striatal cells were grown at 33 C in Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich; St. Louis, MO, USA), supplemented with 10% fetal bovine serum, 1% penicillinstreptomycin, 2 mM l-glutamine, 1 mM sodium pyruvate and 400 lg/ml G418 (Geneticin; GIBCO-BRL, Life technologies; Gaithersburg, MD, USA).
Cell counting kit-8 (CCK-8) assay
CCK-8 assay (Sigma) was performed to evaluate the protective effect of 7,8-DHF (500 nM) and BDNF (10ng/ml) against H2O2. ST/7Q cells were plated into 96-well plates at a density of 3.8 Â 10 3 cells/well, and cultured for 24h. To evaluate effect of the BDNF inhibitor K252a, cells were incubated for 30 min, then treatment combinations were performed on specified wells. 30 min later 90 ml DMEM and 10 ml CCK-8 were added to each well, and the cells were incubated for additional 2 h. Subsequently, the supernatant was removed, and the absorbance at 450 nm wavelength was recorded using a microplate reader (Bio-Rad Laboratories, Inc.). Wells containing 10% CCK-8 (DMEM 90 ml and 10 ml CCK-8) were regarded as blanks. The experiment was performed with 3 repeated measures of each experimental value, and repeated 3 times.
Statistical analysis
All data are expressed as mean 6 SEM. All graphs were created with GraphPad Prism. Different statistical analyses were performed as appropriate, and indicated in the figure legends. Briefly, experimental data were analysed either by two-way ANOVA followed by the post hoc Fisher's LSD test, when the effect of more than one parameter/factor was simultaneously analysed or by Student's t-test, when only one parameter was being analysed. Values of P < 0.05 were considered statistically significant.
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